Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluiddisseminated medulloblastoma

Adam W. Studebaker, Brian Hutzen, Christopher R. Pierson, Stephen J Russell, Evanthia Galanis, Corey Raffel

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Medulloblastoma is the most common malignant brain tumor of childhood. Although the survival rate of afflicted children has improved considerably over the past several years, a subset of these patients will present with disseminated disease and face a much bleaker prognosis. In addition, patients may present with disseminated disease at recurrence. We previously demonstrated the efficacy of a recombinant oncolytic measles virus (MV) to treat localized medulloblastoma in a mouse xenograft model. In the present study, we sought to extend our findings to the treatment of disseminated disease. To this end, we developed and characterized a mouse xenograft model of disseminated medulloblastoma using serial bioluminescent imaging techniques in combination with histopathological examination. Mice injected with medulloblastoma cells into their right lateral ventricle showed tumor growth in their ventricles and in both intracranial and spinal subarachnoid spaces, closely recapitulating the human disease. Subsequent intraventricular administration of MV resulted in stabilization and shrinkage of the tumor, significantly prolonging the survival of the treated animals, compared with those treated with an inactivated virus. These data demonstrate that oncolytic MV may be of use in treating disseminated medulloblastoma. In addition, our protocol of intraventricular tumor cell injection, followed by bioluminescent imaging coupled with histopathological examination, provides a model for use in evaluating future recombinant oncolytic viruses and other preclinical therapeutic approaches for disseminated medulloblastoma.

Original languageEnglish (US)
Pages (from-to)459-470
Number of pages12
JournalNeuro-Oncology
Volume14
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Oncolytic Viruses
Measles virus
Medulloblastoma
Survival
Heterografts
Neoplasms
Subarachnoid Space
Lateral Ventricles
Brain Neoplasms
Heart Ventricles
Survival Rate
Viruses
Recurrence
Injections
Therapeutics
Growth

Keywords

  • bioluminescence
  • dissemination
  • measles virus
  • medulloblastoma
  • oncolytic virus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluiddisseminated medulloblastoma. / Studebaker, Adam W.; Hutzen, Brian; Pierson, Christopher R.; Russell, Stephen J; Galanis, Evanthia; Raffel, Corey.

In: Neuro-Oncology, Vol. 14, No. 4, 04.2012, p. 459-470.

Research output: Contribution to journalArticle

Studebaker, Adam W. ; Hutzen, Brian ; Pierson, Christopher R. ; Russell, Stephen J ; Galanis, Evanthia ; Raffel, Corey. / Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluiddisseminated medulloblastoma. In: Neuro-Oncology. 2012 ; Vol. 14, No. 4. pp. 459-470.
@article{2e97ac399d1f4910b01639c40071f859,
title = "Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluiddisseminated medulloblastoma",
abstract = "Medulloblastoma is the most common malignant brain tumor of childhood. Although the survival rate of afflicted children has improved considerably over the past several years, a subset of these patients will present with disseminated disease and face a much bleaker prognosis. In addition, patients may present with disseminated disease at recurrence. We previously demonstrated the efficacy of a recombinant oncolytic measles virus (MV) to treat localized medulloblastoma in a mouse xenograft model. In the present study, we sought to extend our findings to the treatment of disseminated disease. To this end, we developed and characterized a mouse xenograft model of disseminated medulloblastoma using serial bioluminescent imaging techniques in combination with histopathological examination. Mice injected with medulloblastoma cells into their right lateral ventricle showed tumor growth in their ventricles and in both intracranial and spinal subarachnoid spaces, closely recapitulating the human disease. Subsequent intraventricular administration of MV resulted in stabilization and shrinkage of the tumor, significantly prolonging the survival of the treated animals, compared with those treated with an inactivated virus. These data demonstrate that oncolytic MV may be of use in treating disseminated medulloblastoma. In addition, our protocol of intraventricular tumor cell injection, followed by bioluminescent imaging coupled with histopathological examination, provides a model for use in evaluating future recombinant oncolytic viruses and other preclinical therapeutic approaches for disseminated medulloblastoma.",
keywords = "bioluminescence, dissemination, measles virus, medulloblastoma, oncolytic virus",
author = "Studebaker, {Adam W.} and Brian Hutzen and Pierson, {Christopher R.} and Russell, {Stephen J} and Evanthia Galanis and Corey Raffel",
year = "2012",
month = "4",
doi = "10.1093/neuonc/nor231",
language = "English (US)",
volume = "14",
pages = "459--470",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluiddisseminated medulloblastoma

AU - Studebaker, Adam W.

AU - Hutzen, Brian

AU - Pierson, Christopher R.

AU - Russell, Stephen J

AU - Galanis, Evanthia

AU - Raffel, Corey

PY - 2012/4

Y1 - 2012/4

N2 - Medulloblastoma is the most common malignant brain tumor of childhood. Although the survival rate of afflicted children has improved considerably over the past several years, a subset of these patients will present with disseminated disease and face a much bleaker prognosis. In addition, patients may present with disseminated disease at recurrence. We previously demonstrated the efficacy of a recombinant oncolytic measles virus (MV) to treat localized medulloblastoma in a mouse xenograft model. In the present study, we sought to extend our findings to the treatment of disseminated disease. To this end, we developed and characterized a mouse xenograft model of disseminated medulloblastoma using serial bioluminescent imaging techniques in combination with histopathological examination. Mice injected with medulloblastoma cells into their right lateral ventricle showed tumor growth in their ventricles and in both intracranial and spinal subarachnoid spaces, closely recapitulating the human disease. Subsequent intraventricular administration of MV resulted in stabilization and shrinkage of the tumor, significantly prolonging the survival of the treated animals, compared with those treated with an inactivated virus. These data demonstrate that oncolytic MV may be of use in treating disseminated medulloblastoma. In addition, our protocol of intraventricular tumor cell injection, followed by bioluminescent imaging coupled with histopathological examination, provides a model for use in evaluating future recombinant oncolytic viruses and other preclinical therapeutic approaches for disseminated medulloblastoma.

AB - Medulloblastoma is the most common malignant brain tumor of childhood. Although the survival rate of afflicted children has improved considerably over the past several years, a subset of these patients will present with disseminated disease and face a much bleaker prognosis. In addition, patients may present with disseminated disease at recurrence. We previously demonstrated the efficacy of a recombinant oncolytic measles virus (MV) to treat localized medulloblastoma in a mouse xenograft model. In the present study, we sought to extend our findings to the treatment of disseminated disease. To this end, we developed and characterized a mouse xenograft model of disseminated medulloblastoma using serial bioluminescent imaging techniques in combination with histopathological examination. Mice injected with medulloblastoma cells into their right lateral ventricle showed tumor growth in their ventricles and in both intracranial and spinal subarachnoid spaces, closely recapitulating the human disease. Subsequent intraventricular administration of MV resulted in stabilization and shrinkage of the tumor, significantly prolonging the survival of the treated animals, compared with those treated with an inactivated virus. These data demonstrate that oncolytic MV may be of use in treating disseminated medulloblastoma. In addition, our protocol of intraventricular tumor cell injection, followed by bioluminescent imaging coupled with histopathological examination, provides a model for use in evaluating future recombinant oncolytic viruses and other preclinical therapeutic approaches for disseminated medulloblastoma.

KW - bioluminescence

KW - dissemination

KW - measles virus

KW - medulloblastoma

KW - oncolytic virus

UR - http://www.scopus.com/inward/record.url?scp=84859521436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859521436&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nor231

DO - 10.1093/neuonc/nor231

M3 - Article

C2 - 22307474

AN - SCOPUS:84859521436

VL - 14

SP - 459

EP - 470

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 4

ER -